BIVI vs BNTC

BioVie Inc. vs Benitec Biopharma Inc. — Valuation Comparison 2026

BIVI

Biotechnology
BioVie Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.44
Last close
Models
7/13
Active
VS

BNTC

Biotechnology
Benitec Biopharma Inc.
Quality
4.4
out of 10
Value Trap
45
WARN
Price
$11.56
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BIVI Fair ValueBIVI Upside BNTC Fair ValueBNTC Upside
Bayesian DCF Intrinsic $1.46 +1.2% $6.04 -47.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.27 -84.1% $0.75 -93.5%
Dynamic NAV Asset-Based $7.21 +401.0% $5.93 -48.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BIVI vs BNTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BIVI vs BNTC — Which Stock Is More Undervalued?

BNTC scores higher with a 4.4/10 quality rating vs BIVI's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioVie Inc. (BIVI) and Benitec Biopharma Inc. (BNTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BIVI currently trades at $1.44 with a QOC of 3.2/10, while BNTC trades at $11.56 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).